Prostate cancer specific mortality after 5α-reductase inhibitors medication in benign prostatic hyperplasia patients: systematic review and meta-analysis

Park, Jae Joon; Lee, Hyun Young; Shim, Sung Ryul; Lee, Sang Wook; Kim, Kwang Taek; Kim, Jae Heon

doi:10.1080/13685538.2021.1948993

Cited by 3 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential for 5-ARIs to be used as chemopreventive medications should be re-examined. Multiple meta-analyses have confirmed a relationship between 5-ARIs and prostate cancer, with both finasteride and dutasteride reducing the incidence of overall and lower-grade prostate cancers (45,46,49,50). Knijnik et al observed a RR reduction of 24% for low and intermediate-risk prostate cancer cohorts [RR 0.76, 95% CI: 0.59-0.98, I 2 =0.74%], a similar finding to the PCPT observations (4,46).…”

Section: Prostate Cancermentioning

confidence: 68%

“…This meta-analysis observed no statistically significant difference between high-grade prostate cancer diagnoses and 5-ARI use (RR 0.98, 95% CI: 0.67-1.43, I 2 =75%). Furthermore, they observed no statistically significant difference in prostate cancer-specific mortality rates between the 5-ARI exposure arm and the control arm, a finding supported by three other meta-analyses, along with multiple other publications (42,43,(45)(46)(47)(48)(49)(50)(51).…”

Section: Prostate Cancermentioning

confidence: 71%

“…Findings have been mixed, though many studies have reported no discernible relationship between 5-ARIs and the incidence of high-grade prostate cancer (41)(42)(43)(44). More recently, several notable meta-analyses have been conducted, all of which contend that 5-ARIs do not increase the incidence or risk of high-grade prostate cancer (45,46). Knijnik et al examined the relationship between 5-ARIs and risk-stratified prostate cancer subgroups, metaanalysing 18 studies including ten randomised controlled trials (46).…”

Section: Prostate Cancermentioning

confidence: 99%

See 2 more Smart Citations

5-alpha reductase inhibitors use in prostatic disease and beyond

Chislett¹,

Chen²,

Perera³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

in use today (1,2). Their effect relies on the inhibition of the 5-alpha reductase (5α-reductase) enzyme which aids in the conversion of testosterone to dihydrotestosterone (DHT) (3).Since its introduction, the clinical indication for 5-ARIs has grown from BPH to include androgenetic alopecia (AGA) and hirsutism (1). As more pathological processes are identified as being mediated by DHT, the clinical

show abstract

Section: Prostate Cancermentioning

confidence: 68%

Section: Prostate Cancermentioning

confidence: 71%

Section: Prostate Cancermentioning

confidence: 99%

See 1 more Smart Citation

5-alpha reductase inhibitors use in prostatic disease and beyond

Chislett¹,

Chen²,

Perera³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

“…Hormonal treatment before definitive local therapy leads to a significant change in size of the neoplastic prostate gland reducing the radiotherapy planning target volume of the prostate by 30%-40% and thus may potentially reduce morbidity. Recent clinical studies have shown the benefit of combined hormone and radiation therapy in terms of local control and biochemical disease-free survival [18] . There is in addition now emerging evidence of a benefit in overall survival, though more data is needed here [18][19] .…”

Section: Adjuvant Therapy Of Localised Prostate Cancermentioning

confidence: 99%

“…Recent clinical studies have shown the benefit of combined hormone and radiation therapy in terms of local control and biochemical disease-free survival [18] . There is in addition now emerging evidence of a benefit in overall survival, though more data is needed here [18][19] .…”

Section: Adjuvant Therapy Of Localised Prostate Cancermentioning

confidence: 99%

The pathophysiologic basis of prostate cancer review

Manoharan¹,

Gottam²

2022

Int. J. Sci. Res. Arch.

View full text Add to dashboard Cite

Worldwide, prostate cancer is the most commonly diagnosed malignancy and the sixth leading cause of cancer death in men. Diagnosis is primarily based on prostate-specific antigen (PSA) testing, MRI scans, and prostate tissue biopsies, although PSA testing for screening remains controversial. New diagnostic technologies including risk stratification bioassay tests, germline testing, and various PET scans are now available. When the cancer is limited to the prostate, it is considered localized and potentially curable. If the disease has spread outside the prostate, bisphosphonates, rank ligand inhibitors, hormonal treatment, chemotherapy, radiopharmaceuticals, immunotherapy, focused radiation, and other targeted therapies can be used. This activity is a current, comprehensive review of the evaluation and management of patients with prostate cancer and highlights the role of the interprofessional team in improving care for affected patients. Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCRPC), the disease remains incurable, although men suffering from this disease are living considerably longer.

show abstract

Antiandrogens as Therapies for COVID-19: A Systematic Review

Cani,

Epistolio,

Dazio

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: In 2019, the breakthrough of the coronavirus 2 disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represented one of the major issues of our recent history. Different drugs have been tested to rapidly find effective anti-viral treatments and, among these, antiandrogens have been suggested to play a role in mediating SARS-CoV-2 infection. Considering the high heterogeneity of studies on this topic, we decided to review the current literature. Methods: We performed a systematic review according to PRISMA guidelines. A search strategy was conducted on PUBMED and Medline. Only original articles published from March 2020 to 31 August 2023 investigating the possible protective role of antiandrogens were included. In vitro or preclinical studies and reports not in the English language were excluded. The main objective was to investigate how antiandrogens may interfere with COVID-19 outcomes. Results: Among 1755 records, we selected 31 studies, the majority of which consisted of retrospective clinical data collections and of randomized clinical trials during the first and second wave of the COVID-19 pandemic. Conclusions: In conclusion, we can state that antiandrogens do not seem to protect individuals from SARS-CoV-2 infection and COVID-19 severity and, thus, their use should not be encouraged in this field.

show abstract

Prostate cancer specific mortality after 5α-reductase inhibitors medication in benign prostatic hyperplasia patients: systematic review and meta-analysis

Cited by 3 publications

References 25 publications

5-alpha reductase inhibitors use in prostatic disease and beyond

5-alpha reductase inhibitors use in prostatic disease and beyond

The pathophysiologic basis of prostate cancer review

Antiandrogens as Therapies for COVID-19: A Systematic Review

Contact Info

Product

Resources

About